SCHEMBL2844401

SCHEMBL2844401

O=C1CCC(c2ccc(O)c(F)c2)=NN1

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 12/20 0.54
PDE3A Q14432 12/20 0.54
PDE4B Q07343 7/20 0.54
PDE4A P27815 6/20 0.54
PDE4C Q08493 6/20 0.54
PDE4D Q08499 6/20 0.54
SMN1; SMN2 Q16637 1/20 0.53
KCNH2 Q12809 1/20 0.47
HSD17B1 P14061 1/20 0.46
GPR119 Q8TDV5 1/20 0.45
LMNA P02545 1/20 0.45
NPY1R P25929 1/20 0.45
NPY2R P49146 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11633903 0.88 PDE3B (0.54) PDE3BPDE3APDE4BPDE4APDE4C
SCHEMBL11149621 0.86 PDE3B (0.57) PDE3BPDE3APDE4BPDE4APDE4C
SCHEMBL20703155 0.86 PDE3B (0.57) PDE3BPDE3APDE4BPDE4APDE4C
SCHEMBL20714742 0.84 PDE3B (0.51) PDE3BPDE3APDE4BPDE4APDE4C
SCHEMBL20714430 0.83 PDE3B (0.65) PDE3BPDE3APDE4BPDE4APDE4C
SCHEMBL20714508 0.83 PDE3B (0.67) PDE3BPDE3APDE4BPDE4APDE4C
SCHEMBL9687288 0.82 PDE3B (0.57) PDE3BPDE3APDE4BPDE4APDE4C
SCHEMBL4883210 0.82 PDE3B (0.54) PDE3BPDE3APDE4BPDE4APDE4C
SCHEMBL20703014 0.82 PDE3B (0.54) PDE3BPDE3APDE4BPDE4APDE4C
SCHEMBL11738142 0.80 PDE3B (0.55) PDE3BPDE3APDE4BPDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160335-A1 PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT KYORIN PHARMACEUTICAL CO., LTD. 2010-06-24 US disclosed
US-20100160335-A1 PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT KYORIN PHARMACEUTICAL CO., LTD. 2010-06-24 US disclosed
US-20100160335-A1 PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT KYORIN PHARMACEUTICAL CO., LTD. 2010-06-24 US disclosed
US-20100130738-A1 PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT KYORIN PHARMACEUTICAL CO., LTD. (JP) 2010-05-27 US disclosed
US-20100130738-A1 PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT KYORIN PHARMACEUTICAL CO., LTD. (JP) 2010-05-27 US disclosed
US-20100130738-A1 PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT KYORIN PHARMACEUTICAL CO., LTD. (JP) 2010-05-27 US disclosed
EP-2168959-A1 PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT Kyorin Pharmaceutical Co., Ltd. (JP) 2010-03-31 EP disclosed
EP-2168960-A1 PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT Kyorin Pharmaceutical Co., Ltd. (JP) 2010-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130738-A1 PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT PDE3A, PDE3B, PDE2A PDE3B 2/4885PDE3A 1/4885PDE4B 6/4885
US-20100160335-A1 PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT PDE3A, PDE5A, PDE2A PDE3B 4/4885PDE3A 1/4885PDE4B 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.